Positive FDA tasimelteon review catapults Vanda shares
This article was originally published in Scrip
Executive Summary
The sequential 11-12-13 date turned out to be good luck for Vanda Pharmaceuticals investors, who couldn't help but revel in the good news an FDA medical reviewer backed approval of the company's experimental drug tasimelteon as a circadian regulator to treat non-24-hour disorder (non-24) in patients with total blindness.